Indicaton
We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis.
We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis.